Federal Register / Vol. 87, No. 64 / Monday, April 4, 2022 / Notices 19515 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than May 4, 2022. 

A. Federal Reserve Bank of 

Philadelphia (William Spaniel, Senior 

Vice President) 100 North 6th Street, 

Philadelphia, Pennsylvania 19105– 

1521. Comments can also be sent 

electronically to 

Comments.applications@phil.frb.org: 

1. Fulton Financial Corporation, 

Lancaster, Pennsylvania; to merge with 

Prudential Bancorp, Inc., and thereby 

indirectly acquire Prudential Bank, both 

of Philadelphia, Pennsylvania. 

Board of Governors of the Federal Reserve 

System, March 30, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–07057 Filed 4–1–22; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF DEFENSE 

GENERAL SERVICES 

ADMINISTRATION 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[OMB Control No. 9000–0082; Docket No. 

2022–0053; Sequence No. 11] 

Information Collection; Federal 

Acquisition Regulation Part 7 

Requirements 

AGENCY: Department of Defense (DOD), 

General Services Administration (GSA), 

and National Aeronautics and Space 

Administration (NASA). 

ACTION: Notice and request for 

comments. 

SUMMARY: In accordance with the 

Paperwork Reduction Act of 1995, and 

the Office of Management and Budget 

(OMB) regulations, DoD, GSA, and 

NASA invite the public to comment on 

a revision concerning Federal 

Acquisition Regulation part 7 

requirements. DoD, GSA, and NASA 

invite comments on: Whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of Federal Government 

acquisitions, including whether the 

information will have practical utility; 

the accuracy of the estimate of the 

burden of the proposed information 

collection; ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and ways to minimize the 

burden of the information collection on 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

OMB has approved this information 

collection for use through August 31, 

2022. DoD, GSA, and NASA propose 

that OMB extend its approval for use for 

three additional years beyond the 

current expiration date. 

DATES: DoD, GSA, and NASA will 

consider all comments received by June 

3, 2022. 

ADDRESSES: DoD, GSA, and NASA 

invite interested persons to submit 

comments on this collection through 

https://www.regulations.gov and follow 

the instructions on the site. This website 

provides the ability to type short 

comments directly into the comment 

field or attach a file for lengthier 

comments. If there are difficulties 

submitting comments, contact the GSA 

Regulatory Secretariat Division at 202– 

501–4755 or GSARegSec@gsa.gov. 

Instructions: All items submitted 

must cite OMB Control No. 9000–0082, 

Federal Acquisition Regulation Part 7 

Requirements. Comments received 

generally will be posted without change 

to https://www.regulations.gov, 

including any personal and/or business 

confidential information provided. To 

confirm receipt of your comment(s), 

please check www.regulations.gov, 

approximately two-to-three days after 

submission to verify posting. 

FOR FURTHER INFORMATION CONTACT: 

Carrie Moore, Procurement Analyst, at 

telephone 571–300–5917, or 

carrie.moore@gsa.gov. 

SUPPLEMENTARY INFORMATION: 

A. OMB Control Number, Title, and 

Any Associated Form(s) 

9000–0082, Federal Acquisition 

Regulation Part 7 Requirements. 

B. Need and Uses 

DoD, GSA, and NASA are combining 

OMB Control Nos. for the Federal 

Acquisition Regulation (FAR) by FAR 

part. This consolidation is expected to 

improve industry’s ability to easily and 

efficiently identify burdens associated 

with a given FAR part. The review of 

the information collections by FAR part 

allows improved oversight to ensure 

there is no redundant or unaccounted 

for burden placed on industry. Lastly, 

combining information collections in a 

given FAR part is also expected to 

reduce the administrative burden 

associated with processing multiple 

information collections. 

This justification supports the 

revision of OMB Control No. 9000–0082 

and combines it with the previously 

approved information collection under 

OMB Control No. 9000–0114, with the 

new title ‘‘Federal Acquisition 

Regulation Part 7 Requirements’’. Upon 

approval of this consolidated 

information collection, OMB Control 

No. 9000–0114 will be discontinued. 

The burden requirements previously 

approved under the discontinued 

number will be covered under OMB 

Control No. 9000–0082. 

This clearance covers the information 

that offerors or contractors must submit 

to comply with the following FAR 

requirements: 

FAR clause 52.207–3, Right of First 

Refusal of Employment, requires 

contractors to provide the contracting 

officer, within 120 days of beginning 

contract performance, the names of 

personnel who were: Adversely affected 

or separated from Government 

employment as a result of the contract 

award; and subsequently hired by the 

contractor to perform under the contract 

within 90 days after contract 

performance began. The information 

provided under this clause is used by 

the Government to ensure: Contractor 

compliance with providing the right of 

first refusal to such affected personnel; 

and certain obligations to displaced 

employees are met by the Government. 

FAR provision 52.207–4, Economic 

Purchase Quantity—Supplies, permits 

offerors, who believe that acquisition of 

supplies in quantity different from what 

is being solicited would be more 

advantageous to the Government, to 

recommend with their offer a more 

economic purchase quantity for the 

required supplies. The information 

provided under this provision is used 

by the Government to acquire supplies 

at the total and unit costs most 

advantageous to the Government and to 

develop a database for future 

acquisitions of such items of supply. 

C. Annual Burden 

Respondents: 14,510. 

Total Annual Responses: 14,510. 

Total Burden Hours: 14,530. 

Obtaining Copies: Requesters may 

obtain a copy of the information 

collection documents from the GSA 


khammond on DSKJM1Z7X2PROD with NOTICES
19516 Federal Register / Vol. 87, No. 64 / Monday, April 4, 2022 / Notices 

Regulatory Secretariat Division, by 

calling 202–501–4755 or emailing 

GSARegSec@gsa.gov. Please cite OMB 

Control No. 9000–0082, Federal 

Acquisition Regulation Part 7 

Requirements. 

Janet Fry, 

Director, Federal Acquisition Policy Division, 

Office of Governmentwide Acquisition Policy, 

Office of Acquisition Policy, Office of 

Governmentwide Policy. 

[FR Doc. 2022–06992 Filed 4–1–22; 8:45 am] 

BILLING CODE 6820–EP–P 

GOVERNMENT ACCOUNTABILITY 

OFFICE 

Request for Nominations for the Board 

of Governors of the Patient-Centered 

Outcomes Research Institute (PCORI) 

AGENCY: Government Accountability 

Office (GAO). 

ACTION: Request for letters of 

nomination and resumes. 

SUMMARY: The Patient Protection and 

Affordable Care Act gave the 

Comptroller General of the United 

States responsibility for appointing up 

to 21 members to the Board of 

Governors of the Patient-Centered 

Outcomes Research Institute. In 

addition, the Directors of the Agency for 

Healthcare Research and Quality and 

the National Institutes of Health, or their 

designees, are members of the Board. As 

the result of terms ending in September 

2022, GAO is accepting nominations in 

the following categories: A surgeon, a 

state-licensed integrative health care 

practitioner, a representative of patients 

and health care consumers, a 

representative of device manufacturers 

or developers, a representative of 

pharmaceutical manufacturers or 

developers, and a representative of 

private payers who represents health 

insurance issuers. Nominations should 

be sent to the email address listed 

below. Acknowledgement of 

submissions will be provided within a 

week of submission. 

DATES: Letters of nomination and 

resumes should be submitted no later 

than May 10, 2022, to ensure adequate 

opportunity for review and 

consideration of nominees prior to 

appointment. 

ADDRESSES: Submit letters of 

nomination and resumes to PCORI@

gao.gov. Include PCORI Nomination in 

the subject line of the email. 

FOR FURTHER INFORMATION CONTACT: Ray 

Sendejas at (202) 512–7113 or 

SendejasR@gao.gov if you do not 

receive an acknowledgement or need 

additional information. For general 

information, contact GAO’s Office of 

Public Affairs, (202) 512–4800. 

Authority: Sec. 6301 and Sec. 10602, 

Pub. L. 111–148, 124 Stat. 119, 727, 

1005 (2010); Div. N, Sec. 104, Pub. L. 

116–94, 133 Stat. 2534 (2019). 

Gene L. Dodaro, 

Comptroller General of the United States. 

[FR Doc. 2022–06452 Filed 4–1–22; 8:45 am] 

BILLING CODE 1610–02–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2022–0044] 

CDC Recommendations for Hepatitis B 

Screening and Testing—United States, 

2022; Request for Comment 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

opening of a docket to obtain comment 

on proposed updated recommendations 

for hepatitis B virus (HBV) infection 

screening and testing (Proposed 

Updated Recommendations), including 

hepatitis B screening at least once in a 

lifetime for persons 18 years of age and 

older, using a three-test panel. The 

Proposed Updated Recommendations 

also expand existing risk-based testing 

recommendations to include the 

following populations, activities, 

exposures, or conditions associated with 

increased risk for HBV infection: 

Persons currently or formerly 

incarcerated in a jail, prison, or other 

detention setting; persons with a history 

of sexually transmitted infections or 

multiple sex partners; and persons with 

a history of hepatitis C virus infection. 

The Proposed Updated 

Recommendations are intended to 

inform the practices of and care by U.S. 

healthcare providers and are based on 

scientific evidence of the effectiveness 

and economic value of screening to 

diagnose current HBV infection among 

adults in the United States. 

DATES: Written comments must be 

received on or before June 3, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0044, by either of the following 

methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Viral Hepatitis, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop U12–3, Atlanta, GA 30329, 

Attn: Docket No. CDC–2022–0044. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. Do not 

submit comments by email; CDC does 

not accept comments by email. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Erin 

Conners, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop U12–3, Atlanta, GA 30329; 

Telephone: 404–639–8000; Email: 

DVHpolicy@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data related to any of the Proposed 

Updated Recommendations or 

supporting evidence. In addition, CDC 

invites comments specifically on the 

following questions: 

• Based on the evidence presented in 

the full recommendations document 

(see the Supporting and Related 

Materials tab in the docket), does the 

evidence support the Proposed Updated 

Recommendations for HBV infection 

screening and testing? If not, please 

state the reason why and, if available, 

provide additional evidence for 

consideration. 

• Are CDC’s Proposed Updated 

Recommendations (see Supporting and 

Related Materials) clearly written? If 

not, what changes do you propose to 

make them clearer? 

• If implemented as currently drafted, 

do you believe the Proposed Updated 

Recommendations would result in a 

reduction in HBV infections and 

associated health and financial 

consequences (e.g., patient and 

healthcare costs to treat chronic 

hepatitis B) in the United States? If not, 

please provide an explanation and 

supporting data or evidence. 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 


khammond on DSKJM1Z7X2PROD with NOTICES